🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Apporter des solutions innovantes aux patients en impasse thérapeutique suppose : une stratégie claire, une équipe unie derrière cette mission, des talents complémentaires. Merci Patrice Bégay de m'avoir permis de revenir sur les fondamentaux de l'aventure Jeito.

Le collectif fait la différence dans l'accompagnement que propose JEITO. Dans #SansPeurAvecTalents, Rafaele Tordjman évoque l'importance de la diversité d'expertises et de compétences dans le succès des #biopharmas que nous soutenons. Patrice Bégay La Tribune

Let’s start 2024 with a thrilling announcement! Jeito’s portfolio company #Advesya, a pioneering #biopharma company for difficult-to-treat cancers, has officially stepped out of stealth mode today. Know more about Advesya’s story 👉 jeito.life/en/jeito-capit…

This 42nd edition holds special significance for our portfolio companies as three of them have been selected to participate as speakers for the first time: Noema Pharma, Pulmocide, and Quell Therapeutics. Congratulations to all three 👏 #JPM2024

As part of the founding team and today as a Partner Investor, Ksenija is instrumental to Jeito’s collective success. Thank you for your steady commitment and spirit of excellence alongside our team, and with Advesya.

This week, Jeito is heading to IPEM Cannes! 🚅 🎤 Don't miss out on the presentation of Rafaele Tordjman highlighting the investment opportunities in #healthcare. 📍January 25th at 12 PM in Summit Room 1. We look forward to connecting with you at our booth ⤵

For our first Principles for Responsible Investment Assessment, we are more than happy to achieve a 4⭐️ rating in 3 major categories, which makes Jeito outperform the median score of UNPRI signatories. This rating encourages us to go further in our sustainability journey ⤵️

As we celebrate #IWD2024, we are pleased to share steady significant progress within our portfolio companies regarding #diversity and #inclusion. ➡️ Women made up 34% of the management teams, compared to 27% when we invest ➡️ Women held 28% of Board positions, versus 18%.

I'm very happy to welcome Sarah to our team. Her appointment marks a new milestone in Jeito's growth journey. This new position also reflects our ambition to accelerate the development of our portfolio companies and therapeutic innovations to patients.

#AI opens a new era of therapeutic innovations. At the #FutureOfFinance Conference, I shared convictions on AI as a must have to accelerate therapeutic innovation for the benefit of patients. We can go faster for thousands of patients with high unmet needs!

18 months after Jeito’s initial investment, this exit is evidence of Jeito’s unique investment strategy of targeting pharma demand, selectively sourcing the best opportunities, and validating Jeito’s leading position within a syndicate of high-quality global investors. All proud!

👏Congratulations to our portfolio company SparingVision for being selected once again in the #FT120 Index, highlighting the 120 most promising French companies with the potential to become global leaders in their markets. Proud to support your journey!

🗞️ Check out this article by BioCentury on Biogen's acquisition of HI-Bio: A Biogen Company from Jeito. Paul Bonanos highlights the exceptional quality of Hi-Bio's immunology and the significant value creation milestone achieved in the benefit of the patients👇biocentury.com/article/652489…

Through this new successful exit, Jeito demonstrates how its unique investment strategy and collective expertise bring value to the company, the patients and the investors. I wish the whole EyeBio team great success with Merck! #FasterFortThePatient #privateequity

Jeito Capital enchaîne les «success stories». La société d’investissement cède sa participation dans EyeBio à Merck dans le cadre d’une transaction pouvant atteindre les 3 milliards de dollars. #privateequity agefi.fr/private-equity…

📰 « Deux cessions majeures en une semaine » A lire dans Le Figaro le décryptage de la stratégie de Jeito qui a conduit aux cessions des deux entreprises de notre portefeuille : HI-Bio: A Biogen Company à Biogen et EyeBio à Merck. 👉 lefigaro.fr/societes/jeito…

🎙️ Rafaele Tordjman était sur BFM Business pour revenir sur les 2 cessions de Jeito cette semaine : Hi-Bio et EyeBio. Elles illustrent le succès de la stratégie de notre fonds et la forte demande pour des médicaments innovants pour des maladies sans solution thérapeutique ⤵️

"Privatizing Research to Share Innovation?": Don't miss this exceptional conference at #ReAix featuring Rafaele Tordjman, Founder and CEO of Jeito. Follow online the discussions, Saturday, July 6th at 5 PM 👉 lesrencontreseconomiques.fr/evenements/ses…

Since our first investment in #CatalYm, we have been convinced that company was developing a promising new therapy approach to treat cancer. The recent and very impressive data reported by CatalYm makes us even more committed to renewing our support to its talented team. 👏

Hier matin sur @RadioClassique, j’ai eu le plaisir de revenir sur le rôle et la mission de Jeito dans l'écosystème de l'innovation en santé. 2/3 des maladies connues aujourd'hui n'ont pas de traitement. Nous voulons accélérer pour les patients ! smartlink.ausha.co/le-focus-eco/r…